

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE TITLE PAGES:

Item [56] References Cited, in OTHER PUBLICATIONS:

in Yudin, please replace "Geterotsikicheskikh" with --Geterotsiklicheskikh--

in the first Yamashkin et al., please replace "Chemistry.of" with --Chemistry of--

in Edwards, J., et al., please replace "(1999)" with --(1998)--


in Boyer, M., please replace

"<http://www.australianprescriber.com/magazines/vol19no1/ap19-1-11.htm>(accessed on Jan. 28, 2005)." with --<http://www.australianprescriber.com/magazines/vol19no1/ap19-1-11.htm> (accessed on Jan. 28, 2005).--

in Castillo, P., please replace "o-dihydroxyaromatic" with --o-dihydroxyaromatic--

IN THE SPECIFICATION:

In column 2, beginning at line 7, please replace formulas I-VIII with:





UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

18


PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:



in column 7, beginning at line 15, please replace formulas I-VIII with:




UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

18


PATENT NO. : 7,026,484 B2
 APPLICATION NO. : 10/080926
 DATED : April 11, 2006
 INVENTOR(S) : Lin Zhi et al.

Page 3 of

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:



in column 24, lines 53-67, please replace the structures in Scheme II with:



PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.





It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

in column 57, lines 4-6, please replace
 “(Compound 177, Structure 26 of Scheme IV, where R₂=methyl, R₃=2-hydroxyethyl”
 with –(Compound 177, Structure 26 of Scheme IV, where R₂=methyl, R₃=2-
 hydroxyethyl–

in column 70, line 21, please replace "chloronation" with --chlorination--

IN THE CLAIMS:
Please replace Claims 1, 4, 26, 28, 29, 30, 32, 33, 34, 42, 43, 50, 52, 53, and 60 with the following Claims:

1. A compound of the formula:



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

1072
PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

14
Page 5 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R^1 is selected from among hydrogen, F, Cl, Br, I, NO_2 , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}R^{13}$, substituted C_1-C_8 alkyl, C_1-C_8 haloalkyl and C_1-C_8 heteroalkyl, wherein the haloalkyl and heteroalkyl groups are optionally substituted;

R^2 is selected from among F, Cl, Br, I, CF_3 , CHF_2 , CH_2F , CF_2Cl , CN, CF_2OR^{12} , CH_2OR^{12} , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}R^{13}$, substituted C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkenyl and C_2-C_8 alkynyl, wherein the haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted;

R^3 is selected from among hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R^4 is selected from among hydrogen F, Cl, Br, I, OR^{12} , $NR^{12}R^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkynyl, C_2-C_8 alkenyl, aryl, heteroaryl and arylalkyl wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted;

R^5 is selected from among hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R^6 is selected from among hydrogen F, Cl, Br, I, OR^{12} , $NR^{12}R^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkynyl, C_2-C_8 alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted;

R^7 is selected from among hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl, and heteroalkyl groups are optionally substituted;

R^8 is selected from among hydrogen F, Cl, Br, I, OR^{12} , $NR^{12}R^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkynyl, C_2-C_8 alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^5 and R^7 taken together form a bond; or

R^4 and R^6 taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted; or

R^6 and R^8 taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R^9 and R^{10} each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR^{12} , $NR^{12}R^{13}$, $C_m(R^{12})_{2m}OR^{13}$, SR^{12} , SOR^{12} , SO_2R^{12} , $NR^{12}C(O)R^{13}$, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted;

R^{11} is selected from F, Br, Cl, I, CN, OR^{14} , $NR^{14}R^{13}$, and SR^{14} ;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

18

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

Page 6 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^{12} and R^{13} each independently is selected from the group of hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, heteroaryl and aryl wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted;

R^{14} is selected from among hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, aryl, heteroaryl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted;

R^{15} and R^{16} each independently is selected from among hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_1 - C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

W is O or S;

X is N $\{R^{14}\}$;

Y is selected from among O, S, N $\{R^{12}\}$ and NO $\{R^{12}\}$;

Z is N $\{R^{12}\}$;

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1, wherein R^2 is selected from among F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , substituted C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 heteroalkyl, C_2 - C_4 alkenyl and C_2 - C_4 alkynyl, wherein the haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted.

26. A compound according to claim 1, wherein:

R^6 and R^8 each independently is selected from among hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted; or

R^6 and R^8 taken together form a three to eight membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted.

28. A compound according to claim 1, wherein:

R^1 is selected from among hydrogen, F, Cl, Br, I, substituted C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the haloalkyl and heteroalkyl groups are optionally substituted;

R^2 is selected from among F, Cl, Br, CF_3 , CF_2Cl , CF_2H , CFH_2 , substituted C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein haloalkyl and heteroalkyl groups are optionally substituted; and

R^3 and R^4 each independently is selected from among hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl and C_1 - C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

7 18
Page 7 of 18

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

29. A compound according to claim 28, wherein
R⁵ through R⁸ each independently is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or
R⁶ and R⁸ taken together form a four to six membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted.
30. A compound according to claim 29, wherein:
R⁹ and R¹⁰ each independently is selected from among hydrogen, F, Cl, Br, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;
R¹² is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted; and
R¹⁴ is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, C(O)R¹⁵, CO₂R¹⁵ and C(O)NR¹⁵R¹⁶, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted.
32. A compound according to claim 1, wherein said compound is selected from among:
6-Methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Isopropyl-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Allyl-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-(4-Methoxyphenyl)-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
4-Trifluoromethyl-5,6,7,8-tetrahydrocyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
4-Trifluoromethyl-5,6,7,8,9,10-hexahydrocycloheptano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-Dihydro-5,6-cis-dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(3-furanylmethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(3-thiophenemethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

8 18
Page 8 of 8

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 82, Line 13 should read

(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2-methylpropyl)-4-trifluoromethylcyclopentano
[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2,2-chlorodifluoro-ethyl)-4-
trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-cyclopropylmethyl-4-
trifluoromethylcyclopentano[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2-dimethoxyethyl)-4-trifluoromethylcyclo-
pentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,8,8a(cis)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9H-
cyclohexano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,8,9,9a(cis),10-Octahydro-10-(2,2,2-trifluoroethyl)-4-
trifluoromethylcycloheptano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-
pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-
pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-(4-nitrophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-
trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-(4-dimethylaminophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-
trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-
trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-(3-trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-
trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-(4-fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-
trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-Dihydro-5-phenyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo-3,2-f]-
quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-(4-methoxyphenyl)-6-methyl-4-trifluoromethyl-7H-pyrrolo
[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2-dimethoxyethyl)-4-
trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-cis-Dihydro-5-isopropyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-
7H-pyrrolo[3,2-f]quinolin-2(1H)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

9 18
Page 1 of 1

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo-[3,2-f]quinolin-2(1H)-one;
(±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo-[3,2-f]quinolin-2(1H)-one;
(±)-5,6-Dihydro-5-(2-ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5,6,7,8-Tetrahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;
8-Trifluoroethyl-4-trifluoromethyl-6,8-dihydrocyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
9-Trifluoroethyl-trifluoromethyl-9H-benzo[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
5-(3-Trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-(4-Fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-(2-Ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Methyl-6-(1-hydroxyethyl)-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Methyl-6-acetyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Formyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Acetyloxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
2-Acetyloxy-5-hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinoline;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

id 18

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

Page 4 of 4

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
5-Ethoxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]-
quinolin-2(1H)-one;
(+)-6-(1-Methoxyethyl)-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo-
[3,2-f]quinolin-2(1H)-one;
7-Allyl-6-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;
6-Ethyl-7-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;
7-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2
(1H)-one;
7-(2-Hydroxyethyl)-6-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;
(+)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethyl-
cyclopentano-[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;
(-)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-
trifluoromethylcyclopentano-[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-Dihydro-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-5,6-Dihydro-7-ethyl-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-f]quinolin-2
(1H)-one;
5-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;
6-Formyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]
quinolin-2(1H)-one; and
5,6-Dimethyl-7-(2,2-difluorovinyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-
2(1H)-one.

Col. 84, line 1 should read

33. A compound according to claim 1, wherein said compound is selected from the
group consisting of:

(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-
trifluoromethylcyclopentano-[g]-pyrrolo-[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[g]pyrrolo
[3,2-f]quinolin-2(1H)-one;
(±)-5,6-Dihydro-5,6-cis-dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo
[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[g]pyrrolo-
[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclo-
pentano-[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;
(±)-4c,5,6,7,7a(cis),8-Hexahydro-8 cyclopropylmethyl-4-trifluoromethylcyclopentano
[g]pyrrolo[3,2-f]quinolin-2(1H)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

11 18
Page 4 of 6

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±) 4c,5,6,7,8,8a(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9H-cyclohexano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±) 5,6-*cis* -Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±) 5,6-*cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±) 5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±) 5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(±) 5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;
(+) 4c,5,6,7,7a(*cis*)-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one; and
(-) 4c,5,6,7,7a(*cis*)-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

12. 18


PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

Page 8 of 8


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 84, line 64 should read


34. A pharmaceutical composition, comprising:
a pharmaceutically acceptable carrier; and
a compound of formula:




OR



OR



OR



wherein:

R¹ is selected from among hydrogen, F, Cl, Br, I, NO₂, OR¹², SR¹², SOR¹², SO₂R¹², NR¹²R¹³, C₁-C₈ alkyl, C₁-C₈ haloalkyl and C₁-C₈ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R² is selected from among F, Cl, Br, I, CF₃, CHF₂, CH₂F, CH₂Cl, CN, CF₂OR¹², CH₂OR¹², OR¹², SR¹², SOR¹², SO₂R¹², NR¹²R¹³, substituted C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₂-C₈ alkenyl and C₂-C₈ alkynyl, wherein the haloalkyl, heteroalkyl, alkenyl and alkynyl groups are optionally substituted;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

13 18
Page 1 of 1

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R³ is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R⁴ is selected from among hydrogen, F, Cl, Br, I, OR¹², NR¹²R¹³, SR¹², SO₂R¹², C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₂-C₈ alkynyl, C₂-C₈ alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted;

R⁵ is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R⁶ is selected from among hydrogen, F, Cl, Br, I, OR¹², NR¹²R¹³, SR¹², SO₂R¹², C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₂-C₈ alkynyl, C₂-C₈ alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted;

R⁷ is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R⁸ is selected from among hydrogen, F, Cl, Br, I, OR¹², NR¹²R¹³, SR¹², SO₂R¹², C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₂-C₈ alkynyl, C₂-C₈ alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are optionally substituted; or

R³ and R⁵ taken together form a bond; or

R⁵ and R⁷ taken together form a bond; or

R⁴ and R⁶ taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted; or

R⁶ and R⁸ taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R⁹ and R¹⁰ each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR¹², NR¹²R¹³, C_m(R¹²)_{2m}OR¹³, SR¹², SO₂R¹², NR¹²C(O)R¹³, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted;

R¹¹ is selected from among F, Br, Cl, I, CN, OR¹⁴, NR¹⁴R¹³ and SR¹⁴;

R¹² and R¹³ each independently is selected from among hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted;

hydrogen,

insert

), (comma)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

14 18
Page 4 of 4

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R¹⁴ is selected from among hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, aryl, heteroaryl, C(O)R¹⁵, CO₂R¹⁵ and C(O)NR¹⁵R¹⁶, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted;

R¹⁵ and R¹⁶ each independently is selected from among hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl and C₁-C₈ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

W is O or S;

X is N {R¹⁴};

Y is selected from among O, S, N{R¹²} and NO{R¹²};

Z is N{R¹²};

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]


UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

15 18

Patent
PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

Page 15 of 18

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:



42. A pharmaceutical composition according to claim 34, wherein R¹¹ is selected from among F, Cl, CN, OR¹⁴, NR¹⁴R¹³ and SR¹⁴.

43. A pharmaceutical composition according to claim 42, wherein R¹¹ is selected from among F, Cl, OR¹⁴, SR¹⁴, NR¹⁴R¹³.

50. A pharmaceutical composition according to claim 49, wherein:

R⁵ through R⁸ each independently is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or

R⁶ and R⁸ taken together form a four to six membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted.

52. A pharmaceutical composition according to claim 51 wherein Y is O or S.


UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,026,484 B2
 APPLICATION NO. : 10/080926
 DATED : April 11, 2006
 INVENTOR(S) : Lin Zhi et al.


16 18
 Page of

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


53. A compound of formula:




OR



OR



OR



wherein:

R^1 is selected from among hydrogen, F, Cl, Br, I, NO_2 , OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{R}^{12}$, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ haloalkyl and $\text{C}_1\text{-C}_8$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R^2 is selected from among F, Cl, Br, CF_3 , CHF_2 , CH_2F , CF_2Cl , $\text{CF}_2\text{OR}^{12}$, $\text{CH}_2\text{OR}^{12}$, OR^{12} , SR^{12} , SOR^{12} , SO_2R^{12} , $\text{NR}^{12}\text{R}^{13}$, substituted $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl and $\text{C}_1\text{-C}_6$ heteroalkyl, wherein the haloalkyl, and heteroalkyl groups are optionally substituted;

R^3 is selected from among hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl and $\text{C}_1\text{-C}_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R^4 is selected from among hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl and $\text{C}_1\text{-C}_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R^5 is selected from among hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl and $\text{C}_1\text{-C}_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

17 18
Page 17 of 18

PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R⁶ is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted;

R⁷ is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R⁸ is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted; or

R³ and R⁵ taken together form a bond; or

R⁵ and R⁷ taken together form a bond; or

R⁴ and R⁶ taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R⁶ and R⁸ taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R⁹ and R¹⁰ each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR¹², NR¹²R¹³, C_m(R¹²)_{2m}OR¹³, SR¹², SOR¹², SO₂R¹², NR¹²C(O)R¹³, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted;

R¹¹ is selected from among F, Br, Cl, I, CN, OR¹⁴, NR¹⁴R¹³ and SR¹⁴;

R¹² and R¹³ each independently is selected from among hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted;

R¹⁴ is selected from among hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, aryl, heteroaryl, C(O)R¹⁵, CO₂R¹⁵ and C(O)NR¹⁵R¹⁶, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted;

R¹⁵ and R¹⁶ each independently is selected from among hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl and C₁-C₈ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

W is O or S;

X is N {R¹⁴};

Y is selected from among O, S, N {R¹²} and NO {R¹²};

Z is N {R¹²};

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Note
PATENT NO. : 7,026,484 B2
APPLICATION NO. : 10/080926
DATED : April 11, 2006
INVENTOR(S) : Lin Zhi et al.

18 18
Page 18 of 18

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

60. A compound according to claim 34, wherein:

R⁵ and R⁷ each independently is selected from among hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl and C₁-C₆ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted; or

R⁵ and R⁷ taken together form a bond.

all previously issued Certificates of Correction.

This certificate supersedes

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]